Object

This publication is protected and can be accessed only from certain IPs.
This publication is protected and can be accessed only from certain IPs.

Title: Development of a novel recombinant TRAIL-IFNγ fusion protein for targeted anti-cancer therapy

Abstract:

TRAIL/Apo2L has been catching attention of many researchers focused on the development of cancer therapies since its discovery. The interest in the molecule results from the fact that almost from the very beginning it has been identified as a molecule capable of inducing apoptosis in cancer cells while maintaining safety against healthy cells. Thus, the discovery of TRAIL initiated the exploration of the concept of using Death Receptors in targeted therapies. So far, however, no company has managed to implement the novel drug based on that. The concept of "enriching" TRAIL analogues with domains exhibiting an additional, different than apoptosis, mechanism of action is currently being explored. One of the proposed solutions is to obtain fusions of recombinant Apo2L/TRAIL and human interferon domains. The added value of such structures should be: stimulation of immune system cells to fight cancer, targeted delivery of interferon, extension of t1/2 of recombinant TRAIL and sensitization of cancer cells to TRAIL-induced apoptosis. The recombinant TRAIL-IFN fusion described in this study, shows a significant advantage over the recombinant human variant of TRAIL in most of the research models used – cytotoxic activity in vitro, mechanisms of cell death, cell cycle analysis, cell morphology, in vivo antitumor efficacy. However there may appear following problems in the further develo ; pment of the drug: the stability of the molecule itself (and its formulation) and the selection of the optimal therapeutic dose, to maintain the desired activity and safety profile for both components of the recombinant molecule.

Place of publishing:

Kraków

Level of degree:

2 - studia doktoranckie

Degree discipline:

farmakologia

Degree grantor:

Rada Dyscypliny Nauki farmaceutyczne

Promoter:

Pękala, Elżbieta

Date issued:

2021

Identifier:

oai:dl.cm-uj.krakow.pl:5082

Call number:

ZB-134099

Language:

pol

Access rights:

tylko w bibliotece

Object collections:

Last modified:

Apr 15, 2024

In our library since:

Apr 15, 2024

Number of object content hits:

12

Number of object content views in PDF format

0

All available object's versions:

http://dl.cm-uj.krakow.pl:8080/publication/5083

Show description in RDF format:

RDF

Show description in OAI-PMH format:

OAI-PMH

Edition name Date
ZB-134099 Apr 15, 2024
×

Citation

Citation style:

This page uses 'cookies'. More information